Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews approved treatments for androgenetic alopecia and reports no new research findings, highlighting the need for further studies.

The source does not provide an abstract for this letter to the editor, so specific results regarding the long-term efficacy and safety of dutasteride for male androgenetic alopecia are not reported.

This pilot study found that using skin patting and iontophoresis to deliver a 6% dutasteride gel led to significant improvements in hair density and shaft diameter in men and postmenopausal women with treatment-resistant androgenetic alopecia, with no reported adverse events.

In this study, researchers found that microinfusion of dutasteride using the MMP® technique did not show a statistical difference compared to placebo in clinical assessments for male androgenetic alopecia, though patients reported improvements in the vertex area.

This study found that the Transdermal Delivery System efficiently delivers testosterone systemically and showed bioequivalent hormone concentrations to a known topical gel in healthy males.

This study found that non-daily use of Dutasteride may be more cost-effective and associated with lower cancer incidence than daily use for patients seeking treatment for lower urinary tract symptoms.

This study found that both finasteride and dutasteride significantly reduced L-DOPA-induced dyskinesia in a rat model of Parkinson's disease, with dutasteride showing greater effectiveness at lower doses.

In this study, topical minoxidil 7% with dutasteride 0.5 mg showed higher efficacy but more adverse effects compared to minoxidil 7% with finasteride 1 mg for treating androgenetic alopecia.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

This study concluded that the combination of all-trans-retinoic acid and tocopherol-α is not recommended for treating del(5q) myelodysplastic syndromes due to low efficacy and high incidence of adverse effects.

This study found that both Finasteride and high-dose Atrazine induced hypospadias in male SD rats, establishing a reproducible animal model for this condition.

This collection from the 2021 Manfred Donike Workshop outlines advancements in doping detection, highlighting new test methods and challenges, with a focus on steroidal substances, peptide hormones, and gene doping analysis.

This study found that dutasteride pretreatment reduced certain sedative effects of alcohol and may decrease drinking behavior in adult men, likely by impacting neuroactive steroid levels.

Androgen deprivation therapy might help prevent severe COVID-19, but more research is needed.

This article reviews the impact of dutasteride on hair growth in androgenetic alopecia, finding it significantly increases hair count and width compared to finasteride and placebo, but reports no new results.

In this study using a rat model, discontinuing dutasteride improved some relaxant responses but did not fully restore erectile function, indicating a potential time-dependent detriment of the drug.

This study found that among men unresponsive to finasteride for androgenic alopecia, 56.25% showed significant hair improvement after six months of dutasteride treatment with reasonable adverse effects.

Combining topical dutasteride with microneedling is more effective for hair growth than microneedling alone.

This study highlights that feeding and eating disorders, as well as disordered eating behaviors, are more prevalent among athletes compared to the general population, emphasizing the critical role of athletic trainers in early identification and management.

In this study, oral dutasteride treatment for at least 12 months was associated with either stabilization or improvement of male-pattern hair loss in the majority of patients.

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.

This study found that low-dose dutasteride is effective and safe for treating male androgenetic alopecia, showing significant improvement in hair growth and reduction in hair shedding in most patients.

This report discusses the FDA's rejection of Aveed, a long-acting testosterone injection, due to safety concerns despite divided advisory committee opinions, without presenting new clinical data.

The authors concluded that finasteride should be preferred over dutasteride for treating male androgenetic alopecia, as it better preserves certain important functions.

This review provides a synopsis of 53 cases of temporal triangular alopecia, noting its frequent detection in early childhood and potential association with congenital diseases, but it reports no new clinical findings.

In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.

This report discusses the FDA's third denial of approval for Aveed, a long-acting testosterone injection by Endo Pharmaceuticals, citing continued safety concerns including severe side effects.

This study presents a novel assay that allows for the simultaneous measurement of various androgens and 5α-reductase inhibitors in male serum, facilitating research into the biochemical effects of these inhibitors.

This study suggests that dutasteride may be a viable alternative for Korean men with androgenetic alopecia who do not respond to finasteride, as it improved hair density and thickness in most participants.